ABSTRACT
INTRODUCTION
In Egypt, viral hepatitis along with Schistosoma mansoni infestation is the major cause of chronic liver disease 1 .HCV infection is characterized by increased markers of oxidative stress
2
. Lipid peroxidation products are increased in serum, peripheral blood mononuclear cells (PBMC), and liver specimen from hepatitis patients
3
. Schistosoma mansoni causes liver disease by inducing granulomatous inflammation. This favors formation of reactive oxygen species, including superoxide ions, hydrogen peroxide and hydroxyl radicals all of which may induce lipid peroxidation 4 , so the antioxidant status may play an important role in the development of chronic liver disease.
Paraoxonase is an ester hydrolase that is synthesized almost exclusively in the liver and which circulates in the plasma associated with HDL 5 . PON1 is the best studied member of a family of mammalian enzymes that includes PON2and PON3, which share 60% sequence identity with PON1. PON1 and PON3 reside in the cholesterolcarrying particles HDL (good cholesterol), whereas PON2 is found in many tissues including the liver, Lungs, brain and heart 6 .PON 1 is a 355 amino acid glycoprotein with a molecular weight of approximately 43 kDa, and a serum concentration of about 50 mg/L 7 . PON1 degrades oxidized phospholipids in low-density lipoproteins (LDL) and HDL and, as such, plays a role in the organism's antioxidant system 8-11 .
Alterations in circulating PON1 levels are associated with a variety of diseases involving oxidative stress
12-14
which, as mentioned is associated with chronic hepatic derrangement
15-17
Serum paraoxonase gene is located at position q 21-q 22 on the long arm of chromosome 7, closely linked to the gene of cystic fibrosis. Human paraoxonase gene (PON1) shows two polymorphisms at its coding region (amino acid at positions 192 and 55) and 5 polymorphisms at the promoter regions of PON1 gene (positions 909, 824, 162, 126 and 107) 18 . The coding region of PON 1 gene contains two polymorphic sites: a leucine (L) methionine (M) transition at position 55 (55L/M), and glutamine (Q) to arginine (R) transition at position192(192Q/R)
19 . The polymorphisms affect the hydrolytic activity of the PON1 isoenzymes with respect to certain substrates, such as paraoxon and lipid peroxides
20
. The dominant effect on activity is exerted by the PON1-192 polymorphism. However, the PON1-55 polymorphism also exerts a smaller, but significant, effect on activity 20 . Therefore, the idea of the current study was to measure PON1 activity and its relation to serum MDA, total proteins levels, AST and ALT activities in patients with chronic liver disease and determine whether or not PON1 activity can be a non-invasive marker of estimating the degree of liver damage in patients with chronic liver disease. Also, we investigated the PON1 gene polymorphism and its possible association with chronic liver disease.
METHODS
The present study was conducted in the Medical Biochemistry and Internal Medicine Departments, Faculty of Medicine, Zagazig University.
One hundred subjects were enrolled in this study. All were divided into 4 groups Group І (Control group):
This group comprised 25 subjects (15 males and 10 females). Their age ranged from 25 to 50 years, with a mean value of 35.3±6.5 years. All were volunteers from relatives, colleagues and patients attending the Out Patient Clinics for minor complaint e.g. minor superficial injuries, ear wax…etc. They suffered no illness that might interfere with the present study. No medications were received for the past few weeks.
Group П (Chronic Bilharzial patients):
Twenty five patients (13 males and 12 females) were included in that group. Their age ranged from 27 to 45 years, with a mean value of 34.2±5 years. Bilharizial infestation was detected by assessing bilharizial antibodies (indirect haemagglutination test) and proved by rectal snip examination.
Group Ш (Chronic HCV group):
Twenty five patients (17 males and 8 females) were included in that group. Their age ranged from 30 to 50 years, with a mean value of 38.7±6.4 years. Patients were diagnosed as having chronic HCV by ELISA antibody assessment and confirmed by the presence of HCV-RNA by RT-PCR estimation. All were negative for bilharzial infestation.
Group ІV (Mixed bilharzial and HCV cirrhosis patients):
Twenty five patients (13 males and 12 females) were included in that group. Their age ranged from 35 to 60 years, with a mean value of 45.2±6.9 years.
They were diagnosed as having both chronic pathological liver affection (HCV and bilhariziasis) by history, clinical examination and serological investigation.
All these individuals were subjected to thorough history taking, routine general and abdominal medical examination, plain X-ray of chest and heart, ultasonographic assessment of abdominal organs and routine laboratory investigations (urine and stool analysis, complete blood count….etc) Blood sampling and DNA extraction Six ml fasting venous blood samples were withdrawn from all the subjects and divided into 2 portions: 1. Three ml were placed in glass tubes with K 2 EDTA and genomic DNA was obtained from leukocytes using QIA amp DNA Blood Mini Kit supplied by Qiagen GmbH, (Hilden, Germany). The purified DNA was safely stored at -20°C for later use. 2. Three ml were collected into glass tubes with no anticoagulants, after being incubated at 37C for 20 minutes and centrifuged to obtain serum, then serum were separated and stored at -20C till time of analysis.
Determination of PON Activity
PON1 activity assays were performed with 2 mmol L -1 paraoxon according to the method described by Mackness et al.
21,22
. . For the polymorphism at position 192, sense primer 5'TATTGTTGCTGTGGGACCTGA G 3' and antisense primer 5' CACGCTAAACCCAAATACATCT C 3', which encompass the 192 polymorphic region of the human PON1 gene, were used. For the polymorphism at position 55, sense primer 5'GAAGAGTGATGTATA-GCCCCAG3' and antisense primer 5' TTTAATCC-AGAGCTAATGAAAGCC 3'were used. The PCR reaction mixture contained 100 ng of DNA template, 0.5 µM of each primer, 1.5 mMMgCl, 200 µM of each dNTP and 1 unit of TaqDNA polymerase(QiagenGmbH,Hilden,Ger man). After denaturing the DNA for 5 min at 95°C, the reaction mixture was subjected to 46 cycles of 1 min denaturation at 94°C, 30s of annealing at 61°C and 1 min of extension at 72°C. For the polymorphism at position 192, the 99 bp PCR product was digested with 8 units of AlwI restriction endonuclease (New England Biolabs, Cambridge, MA, U.S.A.) overnight at 37°C, and the digested products were separated by electrophoresis on a 3% (w/v) agarose gel and visualized using ethidium bromide. The R genotype (arginine) contains a unique AlwI restriction site which results in products of 66 and 33 bp, whereas the Q genotype (glutamine) would not be cut, allowing the PON1-192 genotype to be determined. For the PON1-55 polymorphism, the PCR reaction and cycling were the same as described above, except that 30 cycles were carried out. The PCR product (170 bp) was digested with NlaIII (New England Biolabs) in the presence of bovine serum albumin (BSA) (37 °C, overnight), and the digested products were separated and identifed as above. The L genotype (leucine) does not contain an NlaIII site, whereas the M genotpye (methionine) does contain an NlaIII site, giving rise to products of 126 and 44 bp. (Fig 2 and Fig.3 ).
Measurement of Serum MDA Concentration
Serum MDA levels were measured according to a method described elsewhere 24 . The principle of the method was based on the spectrophotometric measurement of the color occurring during the reaction of thiobarbituric acid with MDA. Concentration of thiobarbituric acid reactive substances (TBARS) was calculated by the absorbance coefficient of MDA-thiobarbituric acid complex and expressed in µmol/L. The traditional measures of liver function (serum alanine transaminase (ALT), and aspartate transaminase (AST) activities, as well as total proteins) were analyzed with standard techniques using Milton Roy Spectronic 3000 Array.
RESULTS
The results of the biochemical measurement in different studied groups are shown in (table 1) . Serum activities of liver enzymes were significantly increased in all patient groups.
Serum PON1 activities were found to be significantly lower in all the studied groups in comparison to control group (P<0.001) (Fig.1) .
Also, serum MDA levels were significantly increased in all groups in comparison to control.
PON1 activity was positively correlated with serum total proteins, in group П, Ш and ІV (r = 0.55, 0.54 and 0.71 respectively) and (P<0.001 in all groups) but not in group І (control group). There was significant negative correlation between serum PON1 activity and serum ALT in group II, III and IV (r = -0.58, -0.49 and -0.47, respectively and P<0.001 in group II and P<0.01 in group III and IV). There was also significant negative correlation between serum PON1 activity and serum MDA in group I, II, III, IV (r = -0.75, -0.64, -0.87 and -0.69) and (P<0.001) in all groups (Table 2) .
Relationship between serum PON1 activity and genotypes
The distributions of the two polymorphisms in the control and in the patient groups with liver disease are shown in table (3). There were no significant differences in genotype or allele frequencies between cases and controls for either the PON1192 or PON155 polymorphisms. The mean decreases of serum PON1 activity in the patient groups relative to the control group were similar and independent of the genotype (Fig 4) .
Multiple ANOVA showed that serum PON1 activities were significantly influenced (P<0.001) by both patients group and the polymorphisms PON155 and PON1192. The plasma concentration of MDA was higher in patients carrying the RR isoform (QQ: 69.5±5. 1µmol/L; QR:
52.3±9.4 µmol/L; QQ: 43.3±9µmol/L; P<0.001, RR vs. QR and QQ). In serum PON1 activity, it was the RR homozygote patients who were most able to hydrolyze paraoxon (QQ: 128.0±46.97 U/L; QR: 217±54.4U/L; RR:276.4±47.1U/L; P <0.001, RR and QR vs. QQ) (table4).
The plasma concentration of MDA was higher in patients carrying the LL isoform (P<0.0001, LL vs. ML and MM). In serum PON1 activity, it was the LL homozygote patients who were most able to hydrolyze paraoxon (P <0.001, LL vs. ML and MM) (table 4). 44 . In the present study we investigated the importance of PON1 activity measurement in assessment of the degree of liver damage as well as the effect of PON1 55 and192 polymorphism in patients with chronic liver disease. Serum PON1 activity is reduced in patients with chronic liver disease and that decrease is related to the degree of liver damage as stated by that its level decrease in patients with combined bilharzial and hepatitis C cirrhosis more than in the other two patients groups. The decrease in serum PON1 activity in patients with chronic liver disease could be accepted as an evidence of increased lipid peroxidation since it was shown that a decrease in liver microsomal PON1 activity is an early biochemical change related to lipid peroxidation and liver injury observed in rats with carbon tetrachloride (CCL4)-induced cirrhosis
45
. Additionally, same authors monitored the modulation of these processes by the dietary supplementation with zinc, a metal that possesses antioxidant and antifibrogenic properties. These findings are consistent with those of Ali (2004) 46 who found that the activities of paraoxonase and arylesterase were partially restored in liver and serum by chronic administration of zinc as compared to control mice in experimental S. mansoni model. Also, elevated level of PON1 significantly reduced the extent of liver injury caused by CCL4 adminstration 35 . It has been reported that PON1 is inactivated after hydrolyzing lipids peroxides 34 and this is confirmed in our study by the increased levels of serum MDA in all patient groups.
Another possible explanation may be related to the fact that alteration in HDL structure and composition can affect PON1 activity 47 . It is known that patients with liver disease often present with lecithin: cholesterol acyl transferase deficiency
48
. As a consequence, cholesterol esters synthesis is impaired and HDL shows great changes in shape and structure 49 . Such abnormalities may affect serum PON1 activity.
In our study, serum MDA level was significantly increased in patients with chronic liver disease in relation to control group. Increased serum MDA level is one of the well known indicators of lipid peroxidation. Increased MDA levels and decreased serum PON1 activity reflect increased oxidative damage in patients with chronic liver disease.
There is a wide inter-individual variation in PON1 concentration and activity. That variation is for apart determined by common genetic variants (polymorphism) in the PON1 gene 50 . Regarding the effect of PON1 polymorphisms on serum PON1 activity, the effects of the PON1 192 and PON155 polymorphisms were the same for both patients and control groups. 54 . They demonstrated that patients with chronic hepatitis had a higher frequency of the RR isoform of the 192 polymorphism than healthy subjects and thus subjects carrying the R allele might be more susceptible to developing disease involving an increased oxidative stress 54 . What may appear to be a paradox in thier study is that the genotype associated with a higher frequency in patients with hepatitis is also, associated with a higher PON1 activity in serum. One possible explanation for this could be that the enzyme has multiple active sites serving different purposes, one of which relates to the lipid peroxide decoupling. In support of this hypothesis, it has been demonstrated that the PON1 active site for protection against lipid peroxidation requires a free sulfhydryl group at cysteine-284,whereas the enzyme activity against paraoxon does not
53
.
In an experimental study of Zhang et al.
35
intramuscular electrotransfer of hPON1Q gene led to efficient expression of the PON1 in mice. Elevated level of PON1 significantly reduced the extent of liver injury caused by CCL 4 administration. In addition, the hPON1Q gene transferred mice also, exhibited lower degrees of oxidative stress, reflected by reduced serum MDA concentration, in contrast to their control counterparts. These data provide compelling and mechanistic evidence for the importance of PON1 in regulation of liver injury.
However, in our study the genotype and the allele frequency were statistically nonsignificant between patients with chronic liver disease and controls and this could be probably due to lower number of participants, ethnic difference and to heterogeneous etiology of their diseases.
In conclusion, the present study indicated that decrease in the activities of paraoxonase may play a role in the pathogenesis of chronic liver disease. In addition, serum paraoxonase activity measurement may be a beneficial tool for assessing the degree of liver damage in patients suffering chronic hepatic diseases. Further studies are required to gain further insight on the role of PON1 polymorphism in relation to chronic liver diseases. 
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